Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.79 |
| ▸ | RECQL | P46063 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 7/20 | 0.65 |
| ▸ | DRD3 | P35462 | 7/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10652670 | 0.98 | RAD52 (0.77) | RAD52RECQLDRD2DRD3ADRA2A | |
| SCHEMBL3590422 | 0.88 | RAD52 (1.00) | RAD52RECQLDRD2DRD3ADRA2A | |
| Hydrochloric Acid SCHEMBL10657526 | 0.85 | RAD52 (0.63) | RAD52RECQLDRD2DRD3ADRA2A | |
| SCHEMBL4628121 | 0.83 | DRD3 (0.63) | RAD52RECQLDRD2DRD3ADRA2A | |
| SCHEMBL3312231 | 0.80 | DRD2 (0.57) | RAD52RECQLDRD2DRD3ADRA2A | |
| SCHEMBL7291516 | 0.79 | DRD2 (0.60) | RAD52RECQLDRD2DRD3ADRA2A | |
| Hydrochloric Acid SCHEMBL11395621 | 0.79 | MAPT (0.62) | RAD52RECQLDRD2DRD3ADRA2A | |
| Talipexole SCHEMBL49817 | 0.79 | DRD2 (1.00) | RAD52RECQLDRD2DRD3ADRA2A | |
| Talipexole SCHEMBL5605621 | 0.79 | DRD2 (1.00) | RAD52RECQLDRD2DRD3ADRA2A | |
| SCHEMBL17591539 | 0.78 | DRD3 (0.58) | RAD52RECQLDRD2DRD3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5281591-A | Administering amidoimido ester or thioamidoimido ester derivative | ALLERGAN, INC. (US) | 1994-01-25 | — | — | US | claimed |
| WO-1992021349-A1 | COMBINATIONS OF ALPHA-2 ADRENERGIC AGONISTS WITH ALPHA-3 ANTAGONISTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0399791-A1 | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | ALLERGAN, INC (US) | 1990-11-28 | — | — | EP | claimed |
| JP-3020219-A | — | — | None | — | — | JP | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-2007705-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1846380-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1814535-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | Nitromed, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006102071-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006078995-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| JP-H0320219-A | COMBINATION OF SELECTIVE ALPHA-ADRENERGIC AGONIST AND ANTAGONIST USEFUL IN LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC | 1991-01-29 | — | — | JP | disclosed |
| JP-H00320219-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | RAD52 2912/4885RECQL 1857/4885DRD2 3220/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | RAD52 2851/4885RECQL 1932/4885DRD2 2155/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | RAD52 4403/4885RECQL 2605/4885DRD2 3701/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | RAD52 3843/4885RECQL 1551/4885DRD2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.